Main Article Content
Melanoma, COVID-19, self-detected, moles, restricted physician access
Background: Physician appointments for non-essential care ceased during COVID-19.
Objective: To pilot test a telehealth solution for patients to rule out melanomas and need for surgical biopsies based on genomic analyses of pigmented lesion samples obtained via adhesive patches.
Methods: Surveys assessed SSE anxiety. Under remote clinician guidance, patients or partners obtained samples using adhesive patches (DermTech, La Jolla, CA).
Results: SSE anxiety increased. Guided self-sampling led to molecular risk factor analyses in 7/7 (100%) of cases compared to 9/10 (90%) randomly selected physician-sampled control cases.
Conclusions: Adhesive patch self-sampling under remote physician guidance is a viable specimen collection option.
2. President Trump Expands Telehealth Benefits for Medicare Beneficiaries During COVID-19 Outbreak. March 17, 2020. https://www.cms.gov/newsroom/press-releases/president-trump-expands-telehealth-benefits-medicare-beneficiaries-during-covid-19-outbreak
3. de Carvalho TM, Noels E, Wakkee M, Udrea A, Nijsten T. Development of smartphone apps for skin cancer risk assessment: progress and promise. JMIR Dermatol. 2019;2 (1):e13376.
4. Gerami P, Yao S, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017;76:114-20.
5. Robinson JK, Reavy R, Mallett KA, Turrisi R. Remote partner assisted skin self-examination skills training of melanoma survivors and their partners. Australian J Dermatol. 2019;60 (1):e80-82.
6. Brouha B, Ferris LK, Skelsey MK, et al. Real-world utility of a non-invasive gene expression test to rule out primary cutaneous melanoma: a large US registry study. J Drugs Dermatol. 2020 March, 19 (3).